Key result
Pravastatin brings only ~13% of African-American patients to strict LDL targets ≤/dL.
Why the study?
The LDL-lowering effect of pravastatin in African-American patients and the factors associated with achieving National Cholesterol Education Program-defined target levels needed to be described.
Does pravastatin therapy reduce LDL to NCEP-defined target levels in African-American patients?
Cohort (n=84)
No
Does pravastatin therapy reduce LDL to NCEP-defined target levels in African-American patients?
A substantial proportion of African-American patients on pravastatin do not achieve NCEP-defined LDL targets, highlighting the need for improved drug monitoring and compliance.
Answers are grounded in this paper and cite their sources.
Target achievement drops with stricter LDL goals in this cohort; leaves open whether adherence interventions or alternatives improve control in African-American patients.
Study Objectives. To describe the low‐density lipoprotein cholesterol (LDL)‐lowering effect of pravastatin in African‐American patients and to identify factors associated with achieving National Cholesterol Education Program (NCEP)‐defined target levels. Design. Retrospectively defined cohort study. Setting. Large, government‐owned, teaching hospital. Patients. Eighty‐four African‐American patients starting therapy with pravastatin in October‐November 1997. Measurements and Main Results. Whether or not target LDL concentrations were achieved was used to measure efficacy. Stepwise logistic regression identified the target LDL, baseline LDL, and baseline high‐density lipoprotein cholesterol (HDL) as significant predictors of achieving the target. The proportion of patients achieving their target LDL when that target was below 160, below 130, and 100 mg/dl or below was 64%, 32%, and 13% (p=0.004), respectively. Medical record review identified the reasons for not achieving target as incorrect drug regimen, inadequate lipid monitoring, and noncompliance. Conclusion. These results indicate that substantial numbers of patients receiving lipid‐lowering therapy are not meeting NCEP‐defined targets and that with increased drug monitoring and compliance, improvements in achieving NCEP target LDL levels could be realized.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2000) conducted a cohort in Hyperlipidemia (elevated LDL cholesterol) (n=84). Pravastatin was evaluated on Achievement of National Cholesterol Education Program (NCEP)-defined target LDL cholesterol levels (<160, <130, and ≤100 mg/dl) (p=0.004). Pravastatin therapy achieved target LDL cholesterol levels of <160, <130, and ≤/dl in 64%, 32%, and 13% of African-American patients, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: